EGFR and neoplasm: Both in vitro and in vivo studies on EGFR mutant osimertinib-resistant NSCLC models demonstrated that BBP-398, alone or in combination with osimertinib, an EGFR inhibitor, exhibited a potent tumor-suppressing activity.